<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779909</url>
  </required_header>
  <id_info>
    <org_study_id>H-26461</org_study_id>
    <secondary_id>R21AT003714-01</secondary_id>
    <nct_id>NCT00779909</nct_id>
  </id_info>
  <brief_title>Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model</brief_title>
  <official_title>Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The burden of chronic gingivitis and periodontitis in the US is disproportionately high among
      Non-Hispanic Blacks compared to Non-Hispanic Whites. Chronic gingivitis is a highly prevalent
      chronic inflammatory disease that may progress into periodontitis, a major cause of tooth
      loss, Data from in-vitro and animal studies suggest anti-inflammatory effects of vitamin D;
      however, if and over what dose-range vitamin D may have anti-inflammatory effects in humans
      is uncertain. Recent clinical studies indicate that beneficial effects of vitamin D for
      several important outcomes may occur over a wide range of serum 25-hydroxyvitamin D (25-OHD)
      concentrations, possibly up to concentrations that would require vitamin D intakes ranging
      from 2 to more than 10 ten times higher than the current RDA for vitamin D. Because dark skin
      pigmentation is a potent inhibitor of vitamin D photosynthesis, Non-Hispanic Blacks have much
      lower 25-OHD serum levels than Non-Hispanic Whites. These differences in vitamin D status may
      partially explain the racial disparities in prevalence of chronic gingivitis and
      periodontitis observed in the US.

      We hypothesize that oral cholecalciferol supplementation can reduce susceptibility to
      gingivitis over a wide range of serum 25-OHD concentrations in Non-Hispanic Whites and
      Non-Hispanic Blacks. We propose to conduct a simple, single-center, randomized, double-blind,
      placebo-controlled parallel-group dose-ranging study. We will compare placebo to doses of 500
      IU, 2,500 IU and 5,000 IU vitamin D3 per day. We will compare the severity of gingival
      inflammation that develops in response to a 28-day period of unlimited plaque growth
      (experimental gingivitis) between dosage groups. Furthermore, we will evaluate the
      association between achieved 25-OHD levels and gingival inflammation.

      The results of this study will have several important implications, as dietary vitamin D
      supplementation may be a simple, safe and inexpensive means by which to reduce racial/ethnic
      disparities in gingivitis, as well as to reduce the overall burden of oral disease in the
      population as a whole. The study will elucidate the dose-response relationship of the
      anti-inflammatory effects of vitamin D, which in turn may lead to a revision of the current
      recommendations regarding nutritional supplementation of vitamin D in order to optimize the
      prevention of important medical conditions and diseases and reduce racial health disparities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D is important for healthy bones. More recently, anti-inflammatory effects of vitamin
      D have been found in laboratory and animal studies and vitamin D may be beneficial for
      inflammatory diseases. Gingivitis is a common inflammatory disease of the gums that develops
      in response to bacterial components in dental plaque. The degree to which gingivitis develops
      in response to a given amount of plaque may vary between different individuals. With this
      study, we want to investigate whether oral supplementation with vitamin D can reduce the
      susceptibility to gingivitis in non-Hispanic Whites and African Americans.

      We plan to randomize 120 healthy volunteers (60 Non-Hispanic Whites, 60 Non-Hispanic Blacks)
      during the wintertime who will abstain from oral hygiene measures (brushing, flossing or
      antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and
      development of gingivitis. These subjects will be randomly allocated to receive either oral
      supplementation with placebo, 500 IU, 2500 IU or 5000 IU vitamin D3 per day starting 8 weeks
      prior to the experimental gingivitis period for a total of 12 weeks. The development of
      gingivitis will be measured using clinical indices of gingival inflammation, inflammatory
      biomarker in gingival crevicular fluid (GCF) and GCF volume. Before and after completion of
      the experimental gingivitis phase, all subjects will receive a professional cleaning of their
      teeth to ensure complete resolution of inflammation.Blood samples will be collected at the
      screening examination, baseline, week 7, and after week 12 (end of trial) to determine serum
      levels of 25-hydroxyvitamin D, parathyroid hormone , serum calcium and to archive serum and
      plasma samples. In addition urine samples will be collected at baseline and weeks 4,7 and 12
      to determine calcium excretion and to archive urine samples for future analyses. Mandibular
      and maxillary Modified Gingival Index (MGI) Scores, Plaque Index (PI) scores, and GCF
      sampling to measure volume and assess for biomarkers (TNF-LPH, IL-1 beta, IL-2, IL-12) will
      be done at 8 and 12 weeks.

      Following recruitment and consent those subjects deemed eligible for further screening will
      then be referred to the BUMC GCRC in order to have two components of the screening procedure
      performed:Electrocardiogram and a blood draw to be sent to Quest for analysis of Vit D and
      PTH levels.

      The extent to which gingivitis develops during the 4-week period of plaque accumulation will
      be compared between the two experimental groups. Furthermore, we will evaluate the
      association between serum levels of 25-OHD and the development of gingivitis as well as serum
      markers of inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Sites That Bleed on Probing</measure>
    <time_frame>end of 4 week experimental gingivitis phase</time_frame>
    <description>Assessment of the bleeding index will be performed on oral and buccal sites. The periodontal probe will be moved gently across the marginal gingiva of all teeth of a quadrant. After 30 seconds, absence or presence of bleeding will be scored. The number of bleeding sites is used to calculate the gingival bleeding score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mandibular Modified Gingival Index (MGI) Score</measure>
    <time_frame>week 8 and week 12</time_frame>
    <description>The Modified Gingival Index (MGI) uses non-invasive/no probing and rates mild and moderate inflammation where: 0 = absence of inflammation; 1 = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary; 2 = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary; 3 = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary; 4 = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. The MGI can be obtained by adding the values of each tooth and dividing by the number of teeth examined. The MGI may be scored for all surfaces of all or selected teeth or for selected areas of all or selected teeth. A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maxillary Modified Gingival Index (MGI) Score</measure>
    <time_frame>week 8 and week 12</time_frame>
    <description>The Modified Gingival Index (MGI) uses non-invasive/no probing and rates mild and moderate inflammation where: 0 = absence of inflammation; 1 = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary; 2 = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary; 3 = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary; 4 = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. The MGI can be obtained by adding the values of each tooth and dividing by the number of teeth examined. The MGI may be scored for all surfaces of all or selected teeth or for selected areas of all or selected teeth. A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mandibular Plaque Index (PI) Score</measure>
    <time_frame>week 8 and week 12</time_frame>
    <description>The Turesky plaque index was used. In this index, plaque is identified using a disclosing solution and scored using a 0 to 5 scale in which a score of 0= No plaque, 1= Separate flecks of plaque, 2= continuous band of plaque less or equal 1 mm, 3= Continuous band of plaque greater than 1 mm but less than 1/3 of crown height, 4= Continuous band of plaque greater or equal 1/3 but less or equal 2/3 of crown height, and 5= Continuous band of plaque greater 2/3 of crown height. Each tooth receives 6 individual scores at: mesial, middle, and distal scores for both the facial and lingual surfaces. An individual's score is derived by adding the scores at each site and dividing by the number of sites evaluated. Higher scores denote higher plaque accumulation. Lower scores are more favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maxillary Plaque Index (PI) Score</measure>
    <time_frame>week 8 and week 12</time_frame>
    <description>The Turesky plaque index was used. In this index, plaque is identified using a disclosing solution and scored using a 0 to 5 scale in which a score of 0= No plaque, 1= Separate flecks of plaque, 2= continuous band of plaque less or equal 1 mm, 3= Continuous band of plaque greater than 1 mm but less than 1/3 of crown height, 4= Continuous band of plaque greater or equal 1/3 but less or equal 2/3 of crown height, and 5= Continuous band of plaque greater 2/3 of crown height. Each tooth receives 6 individual scores at: mesial, middle, and distal scores for both the facial and lingual surfaces. An individual's score is derived by adding the scores at each site and dividing by the number of sites evaluated. Higher scores denote higher plaque accumulation. Lower scores are more favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Crevicular Fluid (GCF) Volume</measure>
    <time_frame>week 8 and week 12</time_frame>
    <description>GCF will be collected by placing a filter paper strip at the opening of the gingival crevice. After carefully removing the supragingival plaque from the sampling area, a paper strip will be placed for 30s or until visibly wet. Sampling time will be recorded and GCF volume collected with each sample will be quantified using a Periotron device. GCF volume will be sampled from three mesial sites per subject: The upper left central incisor, the first upper left premolar and the first upper left molar. Should any of these teeth be missing, substitution will occur in the following order (i) the contralateral tooth, (ii) the distally adjacent tooth, or (iii) the distally adjacent tooth of the contralateral tooth. Should a sample be visibly contaminated with blood, the sample will be discarded and substitution will occur as described above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Crevicular Fluid (GCF) Concentrations of TNF-alpha, IL1-beta, IL-2, IL-12</measure>
    <time_frame>week 8 and week 12</time_frame>
    <description>GCF will be collected by placing a filter paper strip at the opening of the gingival crevice. After carefully removing the supragingival plaque from the sampling area, a paper strip will be placed for 30s or until visibly wet. Sampling time will be recorded and GCF volume collected with each sample will be quantified using a Periotron device.
GCF volume will be sampled from three mesial sites per subject: The upper left central incisor, the first upper left premolar and the first upper left molar. Should any of these teeth be missing, substitution will occur in the following order (i) the contralateral tooth, (ii) the distally adjacent tooth, or (iii) the distally adjacent tooth of the contralateral tooth. Should a sample be visibly contaminated with blood, the sample will be discarded and substitution will occur as described above. Concentrations of TNF-alpha, IL-1 beta, IL-2, and IL-12 will be measured and means and SDs will be calculated for each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>week 7, week 12</time_frame>
    <description>The serum calcium blood test measures the total calcium in the participants' blood. The normal range for total serum calcium concentration in adults is 8.9-10.2 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Calcium/Creatinine Ratio</measure>
    <time_frame>week 4, week 7, week 12</time_frame>
    <description>Urinary calcium ratios were calculated from urine samples at week 4, 7, and 12. A normal reference interval for the urine calcium (mg/dL):urine creatinine (mg/dL) ratio is &lt;0.14.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Gingivitis</condition>
  <arm_group>
    <arm_group_label>1- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- Vitamin D3, 500 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3, 500 IU capsule once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3- Vitamin D3, 2500 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3, 2500 IU capsule once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4- Vitamin D3, 5000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3, 5000 IU capsule once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.</description>
    <arm_group_label>2- Vitamin D3, 500 IU</arm_group_label>
    <arm_group_label>3- Vitamin D3, 2500 IU</arm_group_label>
    <arm_group_label>4- Vitamin D3, 5000 IU</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.</description>
    <arm_group_label>1- Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed written consent

          -  healthy subjects age 18-64 years old

          -  serum 25-hydroxyvitamin D concentration &lt;62.5 nmol/L (&lt;25 ng/mL)

        Exclusion Criteria:

          -  increased risk for infectious endocarditis that require antibiotic prophylaxis prior
             to periodontal probing

          -  women who are postmenopausal

          -  pregnancy or planned pregnancy within the period of the trial

          -  Periodontitis (attachment loss ≥4 mm and probing depths≥5 mm on at least one
             interproximal site)

          -  Any need for immediate dental treatment (can be eligible after completion of
             treatment)

          -  history of hypercalcemia, malabsorption syndrome, abnormal sensitivity to vitamin D or
             hypervitaminosis D

          -  &lt; 3 teeth with bleeding on probing

          -  &lt; 20 teeth present or &lt;8 interproximal spaces (i.e., papillae) in upper jaw

          -  mean plaque index &gt; 3

          -  Current smoking or former smoking with cessation &lt;5 years ago

          -  regular use of any medication for prevention or treatment of disease (including
             Aspirin, NSAIDs, corticosteroids, but NOT including contraceptives)

          -  Diabetes mellitus

          -  hypercalcemia (serum calcium &gt; ULN),

          -  hypocalcemia (serum calcium &lt; ULN),

          -  hyperparathyroidism (serum PTH concentration &gt; ULN),

          -  hypoparathyroidism (serum PTH concentration &lt; LLN)

          -  any cardiac rhythm abnormalities on baseline ECG

          -  use of tanning beds/unwillingness to abstain from use of tanning beds during study

          -  planned travel during study period / unwillingness to abstain from travel to the South
             or High Altitudes

          -  unwillingness to abstain from use of any supplements (including vitamin/mineral and
             herbal supplements) during study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul I Garcia, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University School of Dental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Goldman School of Dental Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>May 26, 2017</results_first_submitted>
  <results_first_submitted_qc>August 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2017</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>gingivitis</keyword>
  <keyword>periodontal disease</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>102 potential participants were screened for study eligibility, 61 met various exclusions criteria, and 41 were found to be eligible for randomization. Of the 41 eligible subjects 35 were randomized into the trial. The 6 not randomized were either lost to follow-up or they lost interest and withdrew their consent for further involvement.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1- Placebo</title>
          <description>placebo oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>2- Vitamin D3, 500 IU</title>
          <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>3- Vitamin D3 2500 IU</title>
          <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>4- Vitamin D3 5000 IU</title>
          <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1-Placebo</title>
          <description>placebo oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>2-Vitamin D3, 500 IU</title>
          <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>3-Vitamin D3, 2500 IU</title>
          <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>4-Vitamin D3, 5000 IU</title>
          <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>non-Hispanic Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Sites That Bleed on Probing</title>
        <description>Assessment of the bleeding index will be performed on oral and buccal sites. The periodontal probe will be moved gently across the marginal gingiva of all teeth of a quadrant. After 30 seconds, absence or presence of bleeding will be scored. The number of bleeding sites is used to calculate the gingival bleeding score.</description>
        <time_frame>end of 4 week experimental gingivitis phase</time_frame>
        <population>Data for this outcome measure was not collected on any of the participants as it was overlooked and failure to collect these data did not come to the attention of the PI until after all follow-ups were completed.</population>
        <group_list>
          <group group_id="O1">
            <title>1- Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2- Vitamin D3, 500 IU</title>
            <description>vitamin D3: oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3.Vitamin D3, 2500 IU</title>
            <description>vitamin D3: oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4- Vitamin D3 5000 IU</title>
            <description>vitamin D3: oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Sites That Bleed on Probing</title>
          <description>Assessment of the bleeding index will be performed on oral and buccal sites. The periodontal probe will be moved gently across the marginal gingiva of all teeth of a quadrant. After 30 seconds, absence or presence of bleeding will be scored. The number of bleeding sites is used to calculate the gingival bleeding score.</description>
          <population>Data for this outcome measure was not collected on any of the participants as it was overlooked and failure to collect these data did not come to the attention of the PI until after all follow-ups were completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mandibular Modified Gingival Index (MGI) Score</title>
        <description>The Modified Gingival Index (MGI) uses non-invasive/no probing and rates mild and moderate inflammation where: 0 = absence of inflammation; 1 = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary; 2 = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary; 3 = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary; 4 = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. The MGI can be obtained by adding the values of each tooth and dividing by the number of teeth examined. The MGI may be scored for all surfaces of all or selected teeth or for selected areas of all or selected teeth. A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation.</description>
        <time_frame>week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1- Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2- Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3- Vitamin D3 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4- Vitamin D3 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mandibular Modified Gingival Index (MGI) Score</title>
          <description>The Modified Gingival Index (MGI) uses non-invasive/no probing and rates mild and moderate inflammation where: 0 = absence of inflammation; 1 = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary; 2 = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary; 3 = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary; 4 = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. The MGI can be obtained by adding the values of each tooth and dividing by the number of teeth examined. The MGI may be scored for all surfaces of all or selected teeth or for selected areas of all or selected teeth. A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8wk mandibular MGI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.27"/>
                    <measurement group_id="O2" value="1.76" spread="0.46"/>
                    <measurement group_id="O3" value="1.62" spread="0.44"/>
                    <measurement group_id="O4" value="1.67" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk mandibular MGI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.14"/>
                    <measurement group_id="O2" value="1.97" spread="0.24"/>
                    <measurement group_id="O3" value="2.02" spread="0.20"/>
                    <measurement group_id="O4" value="2.19" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maxillary Modified Gingival Index (MGI) Score</title>
        <description>The Modified Gingival Index (MGI) uses non-invasive/no probing and rates mild and moderate inflammation where: 0 = absence of inflammation; 1 = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary; 2 = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary; 3 = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary; 4 = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. The MGI can be obtained by adding the values of each tooth and dividing by the number of teeth examined. The MGI may be scored for all surfaces of all or selected teeth or for selected areas of all or selected teeth. A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation.</description>
        <time_frame>week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1- Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2- Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3- Vitamin D3 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4- Vitamin D3 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Maxillary Modified Gingival Index (MGI) Score</title>
          <description>The Modified Gingival Index (MGI) uses non-invasive/no probing and rates mild and moderate inflammation where: 0 = absence of inflammation; 1 = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary; 2 = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary; 3 = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary; 4 = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. The MGI can be obtained by adding the values of each tooth and dividing by the number of teeth examined. The MGI may be scored for all surfaces of all or selected teeth or for selected areas of all or selected teeth. A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8wk maxillary MGI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.29"/>
                    <measurement group_id="O2" value="1.63" spread="0.40"/>
                    <measurement group_id="O3" value="1.57" spread="0.39"/>
                    <measurement group_id="O4" value="1.61" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk maxillary MGI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.16"/>
                    <measurement group_id="O2" value="1.87" spread="0.30"/>
                    <measurement group_id="O3" value="1.9" spread="0.30"/>
                    <measurement group_id="O4" value="2.1" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mandibular Plaque Index (PI) Score</title>
        <description>The Turesky plaque index was used. In this index, plaque is identified using a disclosing solution and scored using a 0 to 5 scale in which a score of 0= No plaque, 1= Separate flecks of plaque, 2= continuous band of plaque less or equal 1 mm, 3= Continuous band of plaque greater than 1 mm but less than 1/3 of crown height, 4= Continuous band of plaque greater or equal 1/3 but less or equal 2/3 of crown height, and 5= Continuous band of plaque greater 2/3 of crown height. Each tooth receives 6 individual scores at: mesial, middle, and distal scores for both the facial and lingual surfaces. An individual’s score is derived by adding the scores at each site and dividing by the number of sites evaluated. Higher scores denote higher plaque accumulation. Lower scores are more favorable.</description>
        <time_frame>week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1- Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2- Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3- Vitamin D3 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4- Vitamin D3 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mandibular Plaque Index (PI) Score</title>
          <description>The Turesky plaque index was used. In this index, plaque is identified using a disclosing solution and scored using a 0 to 5 scale in which a score of 0= No plaque, 1= Separate flecks of plaque, 2= continuous band of plaque less or equal 1 mm, 3= Continuous band of plaque greater than 1 mm but less than 1/3 of crown height, 4= Continuous band of plaque greater or equal 1/3 but less or equal 2/3 of crown height, and 5= Continuous band of plaque greater 2/3 of crown height. Each tooth receives 6 individual scores at: mesial, middle, and distal scores for both the facial and lingual surfaces. An individual’s score is derived by adding the scores at each site and dividing by the number of sites evaluated. Higher scores denote higher plaque accumulation. Lower scores are more favorable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8wk mandibular PI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.60"/>
                    <measurement group_id="O2" value="1.77" spread="0.44"/>
                    <measurement group_id="O3" value="1.82" spread="0.46"/>
                    <measurement group_id="O4" value="1.82" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk mandibular PI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="0.71"/>
                    <measurement group_id="O2" value="2.93" spread="0.50"/>
                    <measurement group_id="O3" value="2.74" spread="0.52"/>
                    <measurement group_id="O4" value="2.89" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maxillary Plaque Index (PI) Score</title>
        <description>The Turesky plaque index was used. In this index, plaque is identified using a disclosing solution and scored using a 0 to 5 scale in which a score of 0= No plaque, 1= Separate flecks of plaque, 2= continuous band of plaque less or equal 1 mm, 3= Continuous band of plaque greater than 1 mm but less than 1/3 of crown height, 4= Continuous band of plaque greater or equal 1/3 but less or equal 2/3 of crown height, and 5= Continuous band of plaque greater 2/3 of crown height. Each tooth receives 6 individual scores at: mesial, middle, and distal scores for both the facial and lingual surfaces. An individual’s score is derived by adding the scores at each site and dividing by the number of sites evaluated. Higher scores denote higher plaque accumulation. Lower scores are more favorable.</description>
        <time_frame>week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1- Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2- Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3- Vitamin D3 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4- Vitamin D3 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Maxillary Plaque Index (PI) Score</title>
          <description>The Turesky plaque index was used. In this index, plaque is identified using a disclosing solution and scored using a 0 to 5 scale in which a score of 0= No plaque, 1= Separate flecks of plaque, 2= continuous band of plaque less or equal 1 mm, 3= Continuous band of plaque greater than 1 mm but less than 1/3 of crown height, 4= Continuous band of plaque greater or equal 1/3 but less or equal 2/3 of crown height, and 5= Continuous band of plaque greater 2/3 of crown height. Each tooth receives 6 individual scores at: mesial, middle, and distal scores for both the facial and lingual surfaces. An individual’s score is derived by adding the scores at each site and dividing by the number of sites evaluated. Higher scores denote higher plaque accumulation. Lower scores are more favorable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8wk maxillary PI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.55"/>
                    <measurement group_id="O2" value="1.71" spread="0.44"/>
                    <measurement group_id="O3" value="1.69" spread="0.49"/>
                    <measurement group_id="O4" value="1.68" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 wk maxillary PI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.42"/>
                    <measurement group_id="O2" value="3" spread="0.32"/>
                    <measurement group_id="O3" value="2.81" spread="0.32"/>
                    <measurement group_id="O4" value="2.89" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Crevicular Fluid (GCF) Volume</title>
        <description>GCF will be collected by placing a filter paper strip at the opening of the gingival crevice. After carefully removing the supragingival plaque from the sampling area, a paper strip will be placed for 30s or until visibly wet. Sampling time will be recorded and GCF volume collected with each sample will be quantified using a Periotron device. GCF volume will be sampled from three mesial sites per subject: The upper left central incisor, the first upper left premolar and the first upper left molar. Should any of these teeth be missing, substitution will occur in the following order (i) the contralateral tooth, (ii) the distally adjacent tooth, or (iii) the distally adjacent tooth of the contralateral tooth. Should a sample be visibly contaminated with blood, the sample will be discarded and substitution will occur as described above.</description>
        <time_frame>week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2-Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3-Vitamin D3, 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4-Vitamin D3, 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Crevicular Fluid (GCF) Volume</title>
          <description>GCF will be collected by placing a filter paper strip at the opening of the gingival crevice. After carefully removing the supragingival plaque from the sampling area, a paper strip will be placed for 30s or until visibly wet. Sampling time will be recorded and GCF volume collected with each sample will be quantified using a Periotron device. GCF volume will be sampled from three mesial sites per subject: The upper left central incisor, the first upper left premolar and the first upper left molar. Should any of these teeth be missing, substitution will occur in the following order (i) the contralateral tooth, (ii) the distally adjacent tooth, or (iii) the distally adjacent tooth of the contralateral tooth. Should a sample be visibly contaminated with blood, the sample will be discarded and substitution will occur as described above.</description>
          <units>ul</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8wk GCF volume site 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="12.5"/>
                    <measurement group_id="O2" value="49.1" spread="21.3"/>
                    <measurement group_id="O3" value="37.1" spread="10.0"/>
                    <measurement group_id="O4" value="57.6" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk GCF volume site 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="13.1"/>
                    <measurement group_id="O2" value="66.5" spread="31.8"/>
                    <measurement group_id="O3" value="35.1" spread="7.8"/>
                    <measurement group_id="O4" value="55.9" spread="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8wk GCF volume site 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="9.8"/>
                    <measurement group_id="O2" value="53.5" spread="23.4"/>
                    <measurement group_id="O3" value="42.5" spread="27.4"/>
                    <measurement group_id="O4" value="61.0" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk GCF volume site 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" spread="24.5"/>
                    <measurement group_id="O2" value="71.9" spread="29.5"/>
                    <measurement group_id="O3" value="54.3" spread="24.6"/>
                    <measurement group_id="O4" value="72.4" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8wk GCF volume site 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="32.9"/>
                    <measurement group_id="O2" value="92.9" spread="26.0"/>
                    <measurement group_id="O3" value="58.4" spread="19.7"/>
                    <measurement group_id="O4" value="59.9" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk GCF volume site 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="27.4"/>
                    <measurement group_id="O2" value="99.1" spread="37.7"/>
                    <measurement group_id="O3" value="64.8" spread="20.0"/>
                    <measurement group_id="O4" value="92" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Crevicular Fluid (GCF) Concentrations of TNF-alpha, IL1-beta, IL-2, IL-12</title>
        <description>GCF will be collected by placing a filter paper strip at the opening of the gingival crevice. After carefully removing the supragingival plaque from the sampling area, a paper strip will be placed for 30s or until visibly wet. Sampling time will be recorded and GCF volume collected with each sample will be quantified using a Periotron device.
GCF volume will be sampled from three mesial sites per subject: The upper left central incisor, the first upper left premolar and the first upper left molar. Should any of these teeth be missing, substitution will occur in the following order (i) the contralateral tooth, (ii) the distally adjacent tooth, or (iii) the distally adjacent tooth of the contralateral tooth. Should a sample be visibly contaminated with blood, the sample will be discarded and substitution will occur as described above. Concentrations of TNF-alpha, IL-1 beta, IL-2, and IL-12 will be measured and means and SDs will be calculated for each study arm.</description>
        <time_frame>week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2-Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3-Vitamin D3, 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4-Vitamin D3, 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Crevicular Fluid (GCF) Concentrations of TNF-alpha, IL1-beta, IL-2, IL-12</title>
          <description>GCF will be collected by placing a filter paper strip at the opening of the gingival crevice. After carefully removing the supragingival plaque from the sampling area, a paper strip will be placed for 30s or until visibly wet. Sampling time will be recorded and GCF volume collected with each sample will be quantified using a Periotron device.
GCF volume will be sampled from three mesial sites per subject: The upper left central incisor, the first upper left premolar and the first upper left molar. Should any of these teeth be missing, substitution will occur in the following order (i) the contralateral tooth, (ii) the distally adjacent tooth, or (iii) the distally adjacent tooth of the contralateral tooth. Should a sample be visibly contaminated with blood, the sample will be discarded and substitution will occur as described above. Concentrations of TNF-alpha, IL-1 beta, IL-2, and IL-12 will be measured and means and SDs will be calculated for each study arm.</description>
          <units>pg/site</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8wk TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.14"/>
                    <measurement group_id="O2" value="1.53" spread="1.86"/>
                    <measurement group_id="O3" value="1.34" spread="1.93"/>
                    <measurement group_id="O4" value="1.87" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.04"/>
                    <measurement group_id="O2" value="1.11" spread="1.32"/>
                    <measurement group_id="O3" value="1.73" spread="3.02"/>
                    <measurement group_id="O4" value="7.94" spread="18.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8wk IL-1 beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.00"/>
                    <measurement group_id="O2" value="0.05" spread="0.02"/>
                    <measurement group_id="O3" value="0.04" spread="0.00"/>
                    <measurement group_id="O4" value="0.04" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk IL-1 beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.00"/>
                    <measurement group_id="O2" value="0.04" spread="0.02"/>
                    <measurement group_id="O3" value="0.04" spread="0.00"/>
                    <measurement group_id="O4" value="0.04" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8wk IL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.11" spread="34.83"/>
                    <measurement group_id="O2" value="13.44" spread="2.66"/>
                    <measurement group_id="O3" value="13.13" spread="6.52"/>
                    <measurement group_id="O4" value="13.07" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk IL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.78" spread="17.31"/>
                    <measurement group_id="O2" value="12.5" spread="0.00"/>
                    <measurement group_id="O3" value="12.56" spread="0.18"/>
                    <measurement group_id="O4" value="13.36" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8wk IL-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.22"/>
                    <measurement group_id="O2" value="0.11" spread="0.17"/>
                    <measurement group_id="O3" value="0.03" spread="0.04"/>
                    <measurement group_id="O4" value="0.96" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk IL-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.10"/>
                    <measurement group_id="O2" value="0.06" spread="0.07"/>
                    <measurement group_id="O3" value="0.02" spread="0.01"/>
                    <measurement group_id="O4" value="1.08" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium</title>
        <description>The serum calcium blood test measures the total calcium in the participants' blood. The normal range for total serum calcium concentration in adults is 8.9-10.2 mg/dL.</description>
        <time_frame>week 7, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2-Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3-Vitamin D3, 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4-Vitamin D3, 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium</title>
          <description>The serum calcium blood test measures the total calcium in the participants' blood. The normal range for total serum calcium concentration in adults is 8.9-10.2 mg/dL.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7wk serum calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="0.4"/>
                    <measurement group_id="O2" value="9.1" spread="0.3"/>
                    <measurement group_id="O3" value="9.2" spread="0.3"/>
                    <measurement group_id="O4" value="9.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk serum calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="0.4"/>
                    <measurement group_id="O2" value="9.2" spread="0.5"/>
                    <measurement group_id="O3" value="9.2" spread="0.3"/>
                    <measurement group_id="O4" value="9.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Calcium/Creatinine Ratio</title>
        <description>Urinary calcium ratios were calculated from urine samples at week 4, 7, and 12. A normal reference interval for the urine calcium (mg/dL):urine creatinine (mg/dL) ratio is &lt;0.14.</description>
        <time_frame>week 4, week 7, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-Placebo</title>
            <description>placebo oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2-Vitamin D3, 500 IU</title>
            <description>vitamin D3 500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>3-Vitamin D3, 2500 IU</title>
            <description>vitamin D3 2500 IU oral supplementation once per day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>4-Vitamin D3, 5000 IU</title>
            <description>vitamin D3 5000 IU oral supplementation once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Calcium/Creatinine Ratio</title>
          <description>Urinary calcium ratios were calculated from urine samples at week 4, 7, and 12. A normal reference interval for the urine calcium (mg/dL):urine creatinine (mg/dL) ratio is &lt;0.14.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4wk calcium/creatinine ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.1"/>
                    <measurement group_id="O2" value="0.06" spread="0.03"/>
                    <measurement group_id="O3" value="0.07" spread="0.04"/>
                    <measurement group_id="O4" value="0.09" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7wk calcium/creatinine ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.1"/>
                    <measurement group_id="O2" value="0.07" spread="0.04"/>
                    <measurement group_id="O3" value="0.09" spread="0.02"/>
                    <measurement group_id="O4" value="0.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12wk calcium/creatinine ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.1"/>
                    <measurement group_id="O2" value="0.07" spread="0.03"/>
                    <measurement group_id="O3" value="0.11" spread="0.09"/>
                    <measurement group_id="O4" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1- Placebo</title>
          <description>placebo oral supplementation once per day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>2- Vitamin D3, 500 IU</title>
          <description>vitamin D3, 500 IU capsule once per day for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>3- Vitamin D3 2500 IU</title>
          <description>vitamin D3, 2500 IU capsule once per day for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>4- Vitamin D3 5000 IU</title>
          <description>vitamin D3, 5000 IU capsule once per day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were recruitment delays due to the potential seasonal impact on vitamin D levels from the sun and the research center was relocated. Both resulted in lower enrollment during the funded time frame than originally projected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raul I Garcia, DMD</name_or_title>
      <organization>Boston University School of Dental Medicine</organization>
      <phone>617-638-6385</phone>
      <email>rig@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

